Apremilast: A Novel Drug for Treatment of Psoriasis and Psoriatic Arthritis.

Item

http://www.wikidata.org/entity/Q38702419

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Apremilast: A Novel Drug for Treatment of Psoriasis and Psoriatic Arthritis.

@en

type

Item

label

Apremilast: A Novel Drug for Treatment of Psoriasis and Psoriatic Arthritis.

@en

prefLabel

Apremilast: A Novel Drug for Treatment of Psoriasis and Psoriatic Arthritis.

@en

P1476

Apremilast: A Novel Drug for Treatment of Psoriasis and Psoriatic Arthritis.

@en

P2093

Evelyn Pierce

http://www.w3.org/2001/XMLSchema#string

Mark Bank

http://www.w3.org/2001/XMLSchema#string

Sarah Hamilton

http://www.w3.org/2001/XMLSchema#string

Shi Yun Leong

http://www.w3.org/2001/XMLSchema#string

Stacy L Haber

http://www.w3.org/2001/XMLSchema#string

P2860

Global epidemiology of psoriasis: a systematic review of incidence and prevalence

Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor.

Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis.

Disposition, metabolism and mass balance of [(14)C]apremilast following oral administration.

The impact of co-administration of ketoconazole and rifampicin on the pharmacokinetics of apremilast in healthy volunteers.

Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics.

A polyarticular onset predicts erosive and deforming disease in psoriatic arthritis.

The pharmacokinetic effect of coadministration of apremilast and methotrexate in individuals with rheumatoid arthritis and psoriatic arthritis

Apremilast, a novel phosphodiesterase 4 (PDE4) inhibitor, regulates inflammation through multiple cAMP downstream effectors.

Improvements in patient-reported outcomes with apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of moderate to severe psoriasis: results from a phase IIb randomized, controlled study

P304

282-290

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1060028015627467

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-01-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26783350

http://www.w3.org/2001/XMLSchema#string